Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesInfliximab for the treatment of ulcerative colitis
Expert Review of Gastroenterology & Hepatology, 06/16/09
Eshuis EJ et al. - Infliximab (IFX), an anti-TNF biologic agent, has been demonstrated to offer benefits for the treatment of autoimmune disorders, such as rheumatoid arthritis and Crohn’s disease. Several trials have also investigated the efficacy of IFX for the treatment of ulcerative colitis (UC).
Related Articles
Medical Management of Ulcerative Colitis
Digestive Diseases, 11/09/09
Relevance Score: 70%
Oxidized Form Of A Common Vitamin May Bring Relief For Ulcerative Colitis
ScienceDaily, 10/02/09
Relevance Score: 69%
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
Gastroenterology, 10/06/09
Relevance Score: 68%
Leukocyte apheresis in the management of ulcerative colitis
Saudi Journal of Gastroenterology, 10/05/09
Relevance Score: 68%
Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half, Study Suggests
ScienceDaily, 10/02/09
Relevance Score: 68%
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
The efficacy and safety of telaprevir ? a new protease inhibitor against hepatitis C virus
Expert Opinion on Investigational Drugs, 12/16/09
Clinically-Staged T3N0 Rectal Cancer: Is Preoperative Chemoradiotherapy the Optimal Treatment
Annals of Surgical Oncology, 12/16/09
Patient attitudes towards and experiences with an intervention programme to reduce chronic acid-suppressing drug intake in primary care
The European Journal of General Practice, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor